Beiersdorf AG header image

Beiersdorf AG

BEI

Equity

ISIN DE0005200000 / Valor 324660

Xetra (2025-11-21)
EUR 89.20-1.04%

Beiersdorf AG
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Beiersdorf AG is a global company with a business segment called tesa, which has been operating independently since 2001. tesa is a leading manufacturer of self-adhesive product solutions for industrial customers and consumers, known for its superior technology and high-quality products. The company's business strategy is centered around innovation, constantly working to develop effective solutions for its customers.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (27.10.2025):

Beiersdorf AG delivered solid financial results in the first quarter of 2025, achieving a 2.3% organic sales growth in its Consumer segment despite a high prior-year base and challenges in the travel retail market and strategic repositioning in China. The company's performance aligns with its full-year outlook, driven by robust growth in its Derma and Healthcare businesses, as well as ongoing innovation and market expansion initiatives.

Consumer Segment Growth

The Consumer segment grew organically by 2.3% in Q1 2025, supported by a strong year-over-year base. Excluding China, the Consumer Business saw a 4% organic growth, meeting full-year guidance. NIVEA sales increased by 2.5%, primarily driven by skin care categories and double-digit growth in North America.

Strong Performance in Derma Business

Beiersdorf's Derma brands, including Eucerin and Aquaphor, achieved an impressive 11.4% organic sales growth. This growth was fueled by the success of face and body categories, breakthrough innovations, and strong performance in key markets such as North America and Emerging Markets, where growth reached 18.5%.

Healthcare Business Surges

The Healthcare division, comprising Hansaplast and Elastoplast, reported a remarkable 10.8% organic sales increase. This growth was driven by the launch of the next generation of plasters and ongoing innovation in wound care products, reinforcing Beiersdorf’s leadership in the category.

Challenges for La Prairie and NIVEA in China

La Prairie experienced a 17.5% decline in organic sales due to ongoing challenges in China and the Travel Retail market, leading to significant stock reductions. Similarly, NIVEA faced headwinds from the strategic repositioning in China, impacting overall sales growth. However, these measures are laying the groundwork for future expansion in the key Chinese market.

Innovation and Market Expansion

Beiersdorf continues to invest in innovation, with plans to launch Thiamidol-based products across its core brands in China by 2026. The company also expanded its global presence with successful product launches in India and the U.S., driving significant growth in these regions. Additionally, the luxury brand Chantecaille achieved double-digit growth of 15.9%, further strengthening Beiersdorf’s market position.

Summarized from source with an LLMView Source

Key figures

-27.2%1Y
-14.3%3Y
-9.62%5Y

Performance

22.3%1Y
17.7%3Y
19.2%5Y

Volatility

Market cap

22354 M

Market cap (USD)

Daily traded volume (Shares)

318,083

Daily traded volume (Shares)

1 day high/low

123.5 / 122.65

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Dermapharm Holding SE
Dermapharm Holding SE Dermapharm Holding SE Valor: 40166352
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.42%EUR 35.45
Straumann Holding Ltd
Straumann Holding Ltd Straumann Holding Ltd Valor: 117544866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.60%CHF 95.34
Tecan Group Ltd.
Tecan Group Ltd. Tecan Group Ltd. Valor: 1210019
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.30%CHF 133.00
Siegfried Holding Ltd
Siegfried Holding Ltd Siegfried Holding Ltd Valor: 1428449
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.59%CHF 70.10
COSMO Pharmaceuticals N.V.
COSMO Pharmaceuticals N.V. COSMO Pharmaceuticals N.V. Valor: 32590356
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.97%CHF 67.40
medmix Ltd
medmix Ltd medmix Ltd Valor: 112967710
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.83%CHF 8.34
SHL Telemedicine Ltd
SHL Telemedicine Ltd SHL Telemedicine Ltd Valor: 1128957
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
11.57%CHF 1.35
Fagron SA
Fagron SA Fagron SA Valor: 3425437
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.74%EUR 20.50
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.12%DKK 577.00
Ardent Health Partners Inc
Ardent Health Partners Inc Ardent Health Partners Inc Valor: 136301364
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.12%USD 8.64